As shown in Fig. 1C, PBMC from patients with newly diagnosed (N = 6) or relapsed (N = 3) MM treated with anti-LAG3 had significantly (*p < 0.05) higher T-cell proliferation than with the other clinical grade immune modulators anti-PD1, anti-OX40, and anti-GITR, either in the presence or absence of MM lysate stimulation. The gene discussed is LAG3; the disease is Miyoshi myopathy.